In conclusion, we have devised AcornHRD, an HRD score algorithm that surpasses clinical variables or BRCA1/2 mutation status in effectively identifying tumors with a higher probability of responding to anthracycline-based neoadjuvant therapy in Chinese breast cancer patients. This evidence concerns the gene BRCA1 and breast cancer.